Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
- Conditions
- Stage II Prostate Adenocarcinoma AJCC v7Stage I Prostate Adenocarcinoma AJCC v7Stage III Prostate Adenocarcinoma AJCC v7
- Interventions
- Radiation: External Beam Radiation TherapyOther: Laboratory Biomarker Analysis
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 612
- Registration Number
- NCT03070886
- Locations
- 🇵🇷
Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico
🇺🇸AdventHealth Celebration, Celebration, Florida, United States
🇺🇸GenesisCare USA - Aventura, Aventura, Florida, United States
Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.
- Conditions
- Metastatic Prostatic Adenocarcinoma
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 52
- Registration Number
- NCT03069937
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Radiation: stereotactic body radiosurgery (SBRT)
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT03056638
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Safety and Efficacy of Firmagon® (Degarelix) for Injection
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 368
- Registration Number
- NCT02886598
- Locations
- 🇰🇷
Gangnam Severance Hospital (there may be other sites in this country), Seoul, Korea, Republic of
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
- Conditions
- Stage III Prostate Cancer AJCC v7Stage IV Prostate Cancer AJCC v7Stage III Prostate Adenocarcinoma AJCC v7Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 22
- Registration Number
- NCT02849990
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2024-11-05
- Target Recruit Count
- 885
- Registration Number
- NCT02799706
- Locations
- 🇧🇪
Hopitaux Universitaires Bordet-Erasme - Hopitaux Universitaires Bordet- Institut Jules Bordet, Brussels, Belgium
🇧🇪Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 230
- Registration Number
- NCT02726009
- Locations
- 🇮🇳
Shalby Hospital, Ahmedabad, India
🇮🇳HealthCare Global Enterprises Limited, Bangalore, India
🇮🇳Bodyline Hospitals, Ahmedabad, India
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 545
- Registration Number
- NCT02663908
- Locations
- 🇸🇰
Fakultna nemocnica Nitra, Nitra, Slovakia
🇺🇸Erlanger Health System, Chattanooga, Tennessee, United States
🇨🇦J. Giddens Medicine Professional Corporation, Brampton, Ontario, Canada
Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-11-28
- Target Recruit Count
- 19
- Registration Number
- NCT02560051
- Locations
- 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States
A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT02526784
- Locations
- 🇫🇮
Tampereen yliopistollinen sairaala (there may be other sites in this country), Tampere, Finland
🇫🇷Groupe Hospitalier Pellegrin Tripode (there may be other sites in this country), Bordeaux, France
🇩🇪Universitaetsklinikum Freiburg (there may be other sites in this country), Freiburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.